![](/img/cover-not-exists.png)
Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study
Julio García-Suárez, Helena Bañas, Ignacio Arribas, Dunia De Miguel, Teresa Pascual, Carmen BurgaletaVolume:
136
Year:
2007
Language:
english
Pages:
10
DOI:
10.1111/j.1365-2141.2006.06438.x
File:
PDF, 506 KB
english, 2007